Atuando em parceria estreita com os mais de 50 hospitais e mais de 40 clínicas de oncologia da RDSL, onde atuam aproximadamente 400 oncologistas clínicos e radio-oncologistas, a equipe de pesquisa em oncologia do IDOR tem hoje as condições necessárias para realizar estudos de grande porte e com impacto na literatura científica mundial. Por isso, além de liderar projetos idealizados por seus cientistas, a área de oncologia do IDOR também participa de estudos globais, conduzindo ensaios clínicos patrocinados pelas indústrias farmacêuticas.
As pesquisas em oncologia idealizadas pelo IDOR estão concentradas em três eixos principais. O primeiro deles é o eixo epidemiológico, que tem como objetivo compreender como o câncer aparece na realidade brasileira – uma lacuna importante a se preencher na literatura, que tem dados mais abundantes sobre a epidemiologia da doença em outros países.
No segundo eixo – o molecular –, os pesquisadores coletam tecidos para montar um banco de tumores, gerando dados que poderão contribuir para o entendimento dos fatores preditivos e prognósticos do câncer. Além disso, o conhecimento adquirido permite ao IDOR incrementar sua participação em pesquisas de desenvolvimento de novos fármacos.
Por fim, o eixo das terapias visa o desenvolvimento de novas medicações para tratar pacientes com câncer, com destaque para as imunoterapias. O IDOR vem participando de estudos com foco em uma nova geração de imunoterápicos, buscando também aprofundar o conhecimento na área de terapias celulares.
O grande volume de pacientes atendidos pela RDSL e pela Oncologia D’Or, combinado ao corpo médico qualificado e preparado para apoiar a realização de ensaios clínicos, coloca a pesquisa oncológica desenvolvida pelo IDOR em uma posição de liderança na América Latina.
Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valenca Bueno L, Andrade LMQS, Patrikidou A, Mestre RP, Modesti M, Pignata S, Procopio G, Fornarini G, De Giorgi U, Russo A, Francini E; SPARTACUSS Investigators. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. J Transl Med. 2023 Feb 3;21(1):75. PMID: 36737752; PMCID: PMC9896712.
Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators (Andrade, L). Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. Epub 2023 Mar 23. PMID: 36952634; PMCID: PMC10431499.
Shore ND, Fizazi K, Tammela T, Luz M, Salas MP, Ouellette P, Lago S, Bastos DA, Jansz GK, Carcano FM, Andrade L, Pliskin M, Lazaretti N, Arruda L, Correa JJ, Petrenciuc O, Kappeler C, Sarapohja T, Smith MR. Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial. Journal of Clinical Oncology (Genitourinary Cancers Symposium) 2021 39:6_suppl, 240-240
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O’Shaughnessy J; IMpassion131 investigators. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021 Aug;32(8):994-1004. Epub 2021 Jul 1. PMID: 34219000.
Bonadio RC, Tarantino P, Testa L, Punie K, Pernas S, Barrios C, Curigliano G, Tolaney SM, Barroso-Sousa R. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences? Cancer Treat Rev. 2022 Nov;110:102459. Epub 2022 Aug 18. PMID: 35998514.
Bonadio RC, Moreira OA, Testa L. Breast cancer trends in women younger than 40 years in Brazil. Cancer Epidemiol. 2022 Jun;78:102139. Epub 2022 Mar 12. PMID: 35290906.
Petry V, Bonadio RC, Cagnacci AQC, Senna LAL, Campos RDNG, Cotti GC, Hoff PM, Fragoso MCBV, Estevez-Diz MDP. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome). Fam Cancer. 2020 Jan;19(1):47-53. PMID: 31748977.
da Costa SCS, Bonadio RC, Gabrielli FCG, Aranha AS, Dias Genta MLN, Miranda VC, de Freitas D, Abdo Filho E, Ferreira PAO, Machado KK, Scaranti M, Carvalho HA, Estevez-Diz MDP. Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial. J Clin Oncol. 2019 Nov 20;37(33):3124-3131. Epub 2019 Aug 26. PMID: 31449470.
Bonadio, RRCC; Fogace, RN; Miranda, VC; Diz, MPE. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. Clinics 2018; 73: p.e450s.
Bretas G, Renna NL, Bines J. Practical considerations for expediting breast cancer treatment in Brazil. Lancet Reg Health Am. 2021 Aug 3;2:100028. PMID: 36779036; PMCID: PMC9904000.
Bines J, Small IA, Sarmento R, Kestelman F, Silva S, Rodrigues FR, Faroni L, Gonçalves A, Ebecken E, Maroun P, Millen E, Bonamino M. Does the Sequence of Anthracycline and Taxane Matter? The NeoSAMBA Trial. Oncologist. 2020 Sep;25(9):758-764. Epub 2020 Jun 23. PMID: 32476183; PMCID: PMC7485342.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. Erratum in: N Engl J Med. 2017 Aug 17;377(7):702. Erratum in: N Engl J Med. 2018 Oct 18;379(16):1585. PMID: 28581356; PMCID: PMC5538020.
Bines J, Earl H, Buzaid AC, Saad ED. Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter? Ann Oncol. 2014 Jun;25(6):1079-85.
Bines J, Dienstmann R, Obadia RM, Branco LGP, Quintella DC, Castro TM, Camacho PG, Soares FA, Costa MEF. Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial. Ann Oncol. 2014 Apr;25(4):831-836.
Testa L, Mano M, Arai RJ, Bonadio RC, Serrano SV, Zorzetto MMC, Crocamo S, Smaletz O, Freitas-Junior R, Hoff PM. Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy. Clinics (Sao Paulo). 2021 Oct 11;76:e3146. PMID: 34644735; PMCID: PMC8478140.
Kawahara LT, Costa IBSDS, Barros CCS, Almeida GC, Bittar CS, Rizk SI, Testa L, Moniz CMV, Pereira J, Oliveira GMM, Diz MDPE, Guimarães PO, Pinto IM, Kalil Filho R, Hajjar LA, Hoff PM. Cancer and Cardiovascular Diseases during the COVID-19 Pandemic. Arq Bras Cardiol. 2020 Sep;115(3):547-557. English, Portuguese. PMID: 33027380; PMCID: PMC9363105.
Oliveira LJC, Megid TBC, Rosa DD, Magliano CADS, Assad DX, Argolo DF, Sanches SM, Testa L, Bines J, Kaliks R, Caleffi M, de Melo Gagliato D, Sahade M, Barroso-Sousa R, Corrêa TS, Shimada AK, Batista DN, Musse Gomes D, Cesca MG, Gaudêncio D, Moura LMA, de Araújo JAP, Katz A, Mano MS. Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study. Ther Adv Med Oncol. 2022 Dec 26;14:17588359221141760. PMID: 36601632; PMCID: PMC9806428.
Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J; KEYNOTE-119 investigators. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):499-511. Epub 2021 Mar 4. PMID: 33676601.
Martin M, Hegg R, Kim SB, Schenker M, Grecea D, Garcia-Saenz JA, Papazisis K, Ouyang Q, Lacko A, Oksuzoglu B, Reeves J, Okera M, Testa L, Shimizu C, Denduluri N, Adamchuk H, Dakhil S, Wei R, Forrester T, Fernandez MM, Zimmermann A, Headley D, Johnston SRD. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial. JAMA Oncol. 2022 Aug 1;8(8):1190-1194. PMID: 35653145; PMCID: PMC9164117.
Guindalini RSC, Cormedi MCV, Maistro S, Pasini FS, Branas PCAA, Dos Santos L, de Lima Pereira GF, de Bock GH, Saccaro DM, Katayama MLH, Faraj SF, Safatle-Ribeiro A, Ribeiro Junior U, Diz MDPE, de Gouvêa ACRC, Chammas R, Folgueira MAAK. Frequency of CDH1 germline variants and contribution of dietary habits in early age onset gastric cancer patients in Brazil. Gastric Cancer. 2019 Sep;22(5):920-931. Epub 2019 Mar 20. PMID: 30895400; PMCID: PMC6694034.
Guindalini RSC, Zheng Y, Abe H, Whitaker K, Yoshimatsu TF, Walsh T, Schacht D, Kulkarni K, Sheth D, Verp MS, Bradbury AR, Churpek J, Obeid E, Mueller J, Khramtsova G, Liu F, Raoul A, Cao H, Romero IL, Hong S, Livingston R, Jaskowiak N, Wang X, Debiasi M, Pritchard CC, King MC, Karczmar G, Newstead GM, Huo D, Olopade OI. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers. Clin Cancer Res. 2019 Mar 15;25(6):1786-1794. Epub 2018 Aug 28. PMID: 30154229; PMCID: PMC6395536.
Achatz MI, Caleffi M, Guindalini R, Marques RM, Nogueira-Rodrigues A, Ashton-Prolla P. Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil. JCO Glob Oncol. 2020 Mar;6:439-452. PMID: 32155091; PMCID: PMC7113069.
Felix GES, Guindalini RSC, Zheng Y, Walsh T, Sveen E, Lopes TMM, Côrtes J, Zhang J, Carôzo P, Santos I, Bonfim TF, Garicochea B, Toralles MBP, Meyer R, Netto EM, Abe-Sandes K, King MC, de Oliveira Nascimento IL, Olopade OI. Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil. Breast Cancer Res Treat. 2022 Jun;193(2):485-494. Epub 2022 Mar 30. PMID: 35353237; PMCID: PMC9090684.
Guindalini RSC, Viana DV, Kitajima JPFW, Rocha VM, López RVM, Zheng Y, Freitas É, Monteiro FPM, Valim A, Schlesinger D, Kok F, Olopade OI, Folgueira MAAK. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. Sci Rep. 2022 Mar 9;12(1):4190. PMID: 35264596; PMCID: PMC8907244.
Cavicchioli Buim ME, Gurgel CA, Gonçalves Ramos EA, Lourenço SV, Soares FA. Activation of sonic hedgehog signaling in oral squamous cell carcinomas: a preliminary study. Hum Pathol. 2011 Oct;42(10):1484-90. Epub 2011 Apr 14. PMID: 21496866.
Valverde Lde F, Pereira Tde A, Dias RB, Guimarães VS, Ramos EA, Santos JN, Gurgel Rocha CA. Macrophages and endothelial cells orchestrate tumor-associated angiogenesis in oral cancer via hedgehog pathway activation. Tumour Biol. 2016 Jul;37(7):9233-41. Epub 2016 Jan 15. PMID: 26768620.
Nogueira RLR, de Araújo TBS, Valverde LF, Silva VAO, Cavalcante BRR, Rossi EA, Allahdadi KJ, Dos Reis MG, Pereira TA, Coletta RD, Bezerra DP, de Freitas Souza BS, Dias RB, Rocha CAG. Arsenic Trioxide Triggers Apoptosis of Metastatic Oral Squamous Cells Carcinoma with Concomitant Downregulation of GLI1 in Hedgehog Signaling. Biomedicines. 2022 Dec 19;10(12):3293. PMID: 36552049; PMCID: PMC9775978.
Bacelar Sacramento de Araújo T, de Oliveira Siquara da Rocha L, Torres Andion Vidal M, Cerqueira Coelho PL, Galvão Dos Reis M, Solano de Freitas Souza B, Botelho Pereira Soares M, Almeida Pereira T, Della Coletta R, Pereira Bezerra D, Borges Dias R, Araújo Gurgel Rocha C. GANT61 Reduces Hedgehog Molecule (GLI1) Expression and Promotes Apoptosis in Metastatic Oral Squamous Cell Carcinoma Cells. Int J Mol Sci. 2020 Aug 24;21(17):6076. PMID: 32846867; PMCID: PMC7503713.
Siquara da Rocha LO, Souza BSF, Lambert DW, Gurgel Rocha CA. Cell-in-Cell Events in Oral Squamous Cell Carcinoma. Front Oncol. 2022 Jun 30;12:931092. PMID: 35847959; PMCID: PMC9280122.
Soares A, Monteiro FSM, Maluf FC, Bastos DA, Jardim DL, Sasse AD, Gonçalves E Silva A, Fay AP, da Rosa DAR, Wierman E, Kater F, Schutz FA, de Oliveira FNG, Morbeck IAP, Rinck JA Jr, da Trindade KM, Maia MC, Souza VC, et al. Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG). J Cancer Res Clin Oncol. 2020 Jul;146(7):1829-1845. Epub 2020 May 14. PMID: 32410064; PMCID: PMC7256074.
Werutsky G, Maluf FC, Cronemberger EH, Carrera Souza V, Dos Santos Martins SP, Peixoto F, Smaletz O, Schutz F, Herchenhorn D, Santos T, Mavignier Carcano F, Queiroz Muniz D, Nunes Filho PRS, Zaffaroni F, Barrios C, Fay A. The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels. BMC Cancer. 2019 May 23;19(1):487. PMID: 31122212; PMCID: PMC6533731.
de Cássio Zequi S, da Costa WH, Korkes F, Dos Reis RB, Busato WFS, Matheus WE, da Silva Neto DCV, de Almeida E Paula F, Carvalhal GF, Nogueira L, de Carvalho Fernandes R, Silva AGE, Sasse AD, Fay AP, Jardim DL, Bastos DA, da Rosa DAR, Wierman E, Kater F, Schutz FA, Maluf FC, de Oliveira FNG, Morbeck IAP, Rinck JA, da Trindade KM, Maia MC, Souza VC, Monteiro FSM, Soares A. Renal cell cancer treatment: an expert panel recommendation from the Latin American cooperative group-genitourinary and the Latin American renal cancer group: focus on surgery. Ther Adv Urol. 2019 Sep 9;11:1756287219872324. PMID: 31523281; PMCID: PMC6734614.
Pereira FMT, Silva AGE, Dettino ALA, Cardoso APG, Sasse AD, Kann AG, Dzik C, Herchenhorn D, Jardim DLF, Lopera D, Ayadi M, Salman P, Kopp RAM, De Carvalho RS, Cavallero SRA, Aguiar S, Souza VC, Uson Junior PLS, Soares A. Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries. JCO Glob Oncol. 2021 Apr;7:545-549. PMID: 33856892; PMCID: PMC8162973.
Maluf FC, Pereira FMT, Serrano Uson PL Jr, Bastos DA, Rodrigues da Rosa DA, Wiermann EG, Schutz FA, Kater FR, de Oliveira FNG, Marques Monteiro FS, de Pádua FV, Orlandi FJ, de Almeida Saito HP, Ayadi M, Boghikian PS, Kopp RM, de Carvalho RS, de Fogace RN, de Araújo Cavallero SR, Aguiar S, Souza VC, Sommer SG. Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC). JCO Glob Oncol. 2021 Apr;7:550-558. PMID: 33856896; PMCID: PMC8162577.
Ramos RN, Rodriguez C, Hubert M, Ardin M, Treilleux I, Ries CH, Lavergne E, Chabaud S, Colombe A, Trédan O, Guedes HG, Laginha F, Richer W, Piaggio E, Barbuto JAM, Caux C, Ménétrier-Caux C, Bendriss-Vermare N. CD163+ tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes. Clin Transl Immunology. 2020 Feb 13;9(2):e1108. PMID: 32082570; PMCID: PMC7017151.
Leruste A, *Ramos RN, *Tosello J, Tauziède-Espariat A, Brohard S, Han ZY, Beccaria K, Andrianteranagna M, Caudana P, Nikolic J, Chauvin C, Niborski LL, Manriquez V, Richer W, Masliah-Planchon J, et al. Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors. Cancer Cell. 2019 Dec 9;36(6):597-612.e8. Epub 2019 Nov 7. PMID: 31708437. (*igual contribuição)
Bourdely P, Anselmi G, Vaivode K, Ramos RN, Missolo-Koussou Y, Hidalgo S, Tosselo J, Nuñez N, Richer W, Vincent-Salomon A, Saxena A, Wood K, Lladser A, Piaggio E, Helft J, Guermonprez P. Transcriptional and Functional Analysis of CD1c+ Human Dendritic Cells Identifies a CD163+ Subset Priming CD8+CD103+ T Cells. Immunity. 2020 Aug 18;53(2):335-352.e8. Epub 2020 Jun 30. PMID: 32610077; PMCID: PMC7445430.
Nader GPF, Agüera-Gonzalez S, Routet F, Gratia M, Maurin M, Cancila V, Cadart C, Palamidessi A, Ramos RN, San Roman M, Gentili M, Yamada A, Williart A, Lodillinsky C, Lagoutte E, Villard C, Viovy JL, Tripodo C, Galon J, Scita G, Manel N, Chavrier P, Piel M. Compromised nuclear envelope integrity drives TREX1-dependent DNA damage and tumor cell invasion. Cell. 2021 Sep 30;184(20):5230-5246.e22. Epub 2021 Sep 21. PMID: 34551315.
Nalio Ramos R, Missolo-Koussou Y, Gerber-Ferder Y, Bromley CP, Bugatti M, Núñez NG, Tosello Boari J, Richer W, Menger L, Denizeau J, Sedlik C, Caudana P, Kotsias F, Niborski LL, Viel S, Bohec M, Lameiras S, Baulande S, Lesage L, Nicolas A, Meseure D, Vincent-Salomon A, Reyal F, Dutertre CA, Ginhoux F, Vimeux L, Donnadieu E, Buttard B, Galon J, Zelenay S, Vermi W, Guermonprez P, Piaggio E, Helft J. Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. Cell. 2022 Mar 31;185(7):1189-1207.e25. Epub 2022 Mar 23. PMID: 35325594.
Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep. 2019 Mar 18;1(1):17-29. PMID: 32039350; PMCID: PMC7001551.
Da Fonseca LG, Hashizume PH, de Oliveira IS, Izquierdo-Sanchez L, Saud LRDC, Xerfan MP, Alves VAF, de Mello ES, Herman P, Banales JM, Oliveira CP, Carrilho FJ. Association between Metabolic Disorders and Cholangiocarcinoma: Impact of a Postulated Risk Factor with Rising Incidence. Cancers (Basel). 2022 Jul 18;14(14):3483. PMID: 35884542; PMCID: PMC9323381.
Díaz-González Á, Sanduzzi-Zamparelli M, Sapena V, Torres F, LLarch N, Iserte G, Forner A, da Fonseca L, Ríos J, Bruix J, Reig M. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther. 2019 Mar;49(5):482-491. Epub 2019 Jan 29. PMID: 30695819.
da Fonseca LG, Reig M, Bruix J. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. Clin Liver Dis. 2020 Nov;24(4):719-737. Epub 2020 Sep 28. PMID: 33012455.
Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):617-630. Epub 2019 Aug 1. PMID: 31371809.
Araujo LH, Baldotto CS, Monteiro MR, Aguiar PN, Andrade MC, Longo CL, Batista M, Lima R, Azevedo D, Carvalho N, Andrade P, Zukin M, Teich N. Patient-centered outcomes in non-small-cell lung cancer: a real-world perspective. Future Oncol. 2021 May;17(14):1721-1733. Epub 2021 Feb 25. PMID: 33626916.
Mak, K. S., Bommel, A. C. M. V., Stowell, C., Abrahm, J. L., Baker, M., Baldotto, C., Baldwin, D. R., Borthwick, D., Carbone, D. P., Chen, A. B., Haswell, T., Koczywas, M., Kozower, B. D., Mehran, R. J., Schramel, F. M., Senan, S., Stirling, R. G., Meerbeeck, J. P. van, Wouters, M. W. J. M., & Peake, M. D. (2015). Defining a Standard Set of Patient Centered Outcomes for Patients With Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 93(3), E403.
Zukin M, Barrios CH, Pereira JR, Ribeiro Rde A, Beato CA, do Nascimento YN, Murad A, Franke FA, Precivale M, Araujo LH, Baldotto CS, Vieira FM, Small IA, Ferreira CG, Lilenbaum RC. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol. 2013 Aug 10;31(23):2849-53. Epub 2013 Jun 17. PMID: 23775961.
Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, Baldotto C, Bennouna J, Shepherd FA, Le-Guennec S, Rey A, Miller V, Thatcher N, Scagliotti G. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol. 2012 Oct 10;30(29):3640-7. Epub 2012 Sep 10. PMID: 22965962.
Baldotto CS, Cronemberger EH, de Biasi P, Zamboni M, Sousa A, Zukin M, Small IA, Ferreira CG. Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy? Support Care Cancer. 2012 Nov;20(11):2721-7. Epub 2012 Feb 10. PMID: 22322592.
Braghiroli MI, Sabbaga J, Hoff PM. Bevacizumab: overview of the literature. Expert Rev Anticancer Ther. 2012 May;12(5):567-80. PMID: 22594892.
Doki, Y., Ajani, J. A., Kato, K., Xu, J., Wyrwicz, L., Motoyama, S., Ogata, T., Kawakami, H., Hsu, C.-H., Adenis, A., El Hajbi, F., Di Bartolomeo, M., Braghiroli, M. I., et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. New England Journal of Medicine, 2022, 386(5), 449–462.
Connell LC, Mota JM, Braghiroli MI, Hoff PM. The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment. Curr Treat Options Oncol. 2017 Apr;18(4):23. PMID: 28391421.
Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Oct 1;6(10):1571-1580. PMID: 32880601; PMCID: PMC7489405.
Sales ARK, Negrão MV, Testa L, Ferreira-Santos L, Groehs RVR, Carvalho B, Toschi-Dias E, Rocha NG, Laurindo FRM, Debbas V, Rondon MUPB, Mano MS, Hajjar LA, Hoff PMG, Filho RK, Negrão CE. Chemotherapy acutely impairs neurovascular and hemodynamic responses in women with breast cancer. Am J Physiol Heart Circ Physiol. 2019 Jul 1;317(7):H1-H12. Epub 2019 Apr 19. PMID: 31002284.
Mascarenhas E, Gelatti AC, Araújo LH, Baldotto C, Mathias C, Zukin M, Werutsky G, Pacheco P, Gomes R, de Castro G Jr, Cordeiro de Lima VC. Comprehensive genomic profiling of Brazilian non-small cell lung cancer patients (GBOT 0118/LACOG0418). Thorac Cancer. 2021 Mar;12(5):580-587. Epub 2020 Dec 13. PMID: 33314759; PMCID: PMC7919136.
Rivelli TG, Mak MP, Martins RE, da Costa e Silva VT, de Castro G Jr. Cisplatin based chemoradiation late toxicities in head and neck squamous cell carcinoma patients. Discov Med. 2015 Jul-Aug;20(108):57-66. PMID: 26321088.
Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, et al. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. J Clin Oncol. 2022 Dec 6:JCO2200332. Epub ahead of print. PMID: 36473143.
Caparica R, Mak MP, Rocha CH, Velho PHI, Viana P, Moura MRL, Menezes MR, Amato MBP, Feher O. Pulmonary nodules in patients with nonpulmonary cancer: not always metástases. J Glob Oncol. 2016 Feb 3;2(3):138-144. eCollection 2016 Jun. PMID: 28717693
Mak MP, Pasini FS, Diao L, Garcia FOT, Takahashi TK, Nakazato D, Martins RE, Almeida CM, Kulcsar MAV, Lamounier VA, Nunes EM, de Souza IC, Garcia MRT, Amadio AV, Siqueira SAC, Snitcovsky IML, Sichero L, Wang J, de Castro G Jr. Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers. e-cancer medical science. 2020 Dec 15;14:1155. eCollection 2020.PMID: 33574900
Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res. 2016 Feb 1;22(3):609-20. Epub 2015 Sep 29. PMID: 26420858.
Coelho JC, de Souza Carvalho G, Chaves F, de Marchi P, de Castro G Jr, Baldotto C, Mascarenhas E, Pacheco P, Gomes R, Werutsky G, Araujo LH. Non-Small-Cell Lung Cancer With CNS Metastasis: Disparities From a Real-World Analysis (GBOT-LACOG 0417). JCO Glob Oncol. 2022 Mar;8:e2100333. PMID: 35467932; PMCID: PMC9067364.
Fares AF, Martinez PH, Farina PH, Bicalho de Souza I, Araújo DV, Paiva NS, Orlando LF, Colombo TE, Mascarenhas E, Gelatti ACZ, Baldotto C, Zukin M, Araujo LH, Mathias C, Werutsky G, de Castro G Jr, Cordeiro de Lima VC. Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil. JTO Clin Res Rep. 2022 Aug 30;3(10):100402. PMID: 36193188; PMCID: PMC9526154.
Gelatti ACZ, Cordeiro de Lima VC, Freitas H, Werutsky G, Gaiger AM, Klock C, Viola PP, Shiang C, de Macedo MP, Lopes LF, De Marchi P, Albino da Silva EC, Moura F, Borges G, Zaffaroni F, Nunes Filho PR, Araujo LH, Mascarenhas E, Mathias C, Barrios C, Zukin M. Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 Nov;21(6):e511-e515. Epub 2020 Apr 13. PMID: 32389509.
Simoes Correa-Galendi, J., del Pilar Estevez Diz, M., Stock, S., Müller, D. Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer. Appl Health Econ Health Policy 19, 97–109 (2021).
Lambertini M, Ameye L, Hamy AS, Zingarello A, Poorvu PD, Carrasco E, Grinshpun A, Han S, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Cortesi L, Senechal C, Miolo G, Pogoda K, Pérez-Fidalgo JA, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz MDP, et al. Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations. J Clin Oncol. 2020 Sep 10;38(26):3012-3023. Epub 2020 Jul 16. PMID: 32673153.
O’Malley DM, Oaknin A, Monk BJ, Selle F, Rojas C, Gladieff L, Berton D, Leary A, Moore KN, Estevez-Diz MDP, Hardy-Bessard AC, Alexandre J, Opperman CP, de Azevedo CRAS, Randall LM, Feliu WO, Ancukiewicz M, Ray-Coquard I. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecol Oncol. 2021 Nov;163(2):274-280. Epub 2021 Aug 25. PMID: 34452745.
Oza AM, Estevez-Diz M, Grischke EM, Hall M, Marmé F, Provencher D, Uyar D, Weberpals JI, Wenham RM, Laing N, Tracy M, Freshwater T, Lee MA, Liu J, Qiu J, Rose S, Rubin EH, Moore K. A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. Clin Cancer Res. 2020 Sep 15;26(18):4767-4776. Epub 2020 Jul 1. PMID: 32611648.
da Costa SCS, Bonadio RC, Gabrielli FCG, Aranha AS, Dias Genta MLN, Miranda VC, de Freitas D, Abdo Filho E, Ferreira PAO, Machado KK, Scaranti M, Carvalho HA, Estevez-Diz MDP. Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial. J Clin Oncol. 2019 Nov 20;37(33):3124-3131. Epub 2019 Aug 26. PMID: 31449470.
Werutsky G, Maluf FC, Cronemberger EH, Carrera Souza V, Dos Santos Martins SP, Peixoto F, Smaletz O, Schutz F, Herchenhorn D, Santos T, Mavignier Carcano F, Queiroz Muniz D, Nunes Filho PRS, Zaffaroni F, Barrios C, Fay A. The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels. BMC Cancer. 2019 May 23;19(1):487. PMID: 31122212; PMCID: PMC6533731.
Maluf F, Soares A, Avanço G, Hada AL, Cardoso APG, Carneiro A, Herchenhorn D, Jardim DLF, Schutz FA, Kater FR, Pereira FMT, Monteiro FSM, Morbeck IAP, Reolon JFN, da Trindade KM, Andrade LMQDS, Nogueira LM, Furoni R, Natel RA, Dos Reis RB, Fogace RN, Souza VC. Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician’s perception according to patient comorbidities. Int Braz J Urol. 2021 Mar-Apr;47(2):359-373. PMID: 33284538; PMCID: PMC7857750.
Maluf FC, Pereira FMT, Silva AG, Dettino ALA, Cardoso APG, Sasse AS, Soares A, Kann AG, Herchenhorn D, Jardim DLF, Cortés DEL, Kater FR, Morbeck IAP, Reolon JFN, Rinck JA Jr, Zarbá JJ, Sade JP, da Trindade KM, Costa LAGA, Dos Santos LV, Maia MC, Siqueira MB, Gillessen S. Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC). JCO Glob Oncol. 2021 Apr;7:559-571. PMID: 33856891; PMCID: PMC8162971.
Treistman N, Nobre GM, Tramontin MY, da Silva GMW, Herchenhorn D, de Lima Araujo LH, de Andrade FA, Corbo R, Bulzico D, Vaisman F. Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors – a single Brazilian center experience. Arch Endocrinol Metab. 2021 Nov 3;65(4):411-420. Epub 2021 Apr 29. PMID: 33939907.
Herchenhorn D, Freire V, Oliveira T, Tarouquella J. Sequential therapies for advanced urothelial cancer: Hope meets new challenges. Crit Rev Oncol Hematol. 2021 Apr;160:103248. Epub 2021 Mar 13. PMID: 33727199.
Venchiarutti Moniz, C.M.; Arai, Roberto J.; Mak, Milena P.; Diz, Maria Del Pilar Estevez; Hoff, Paulo M. Going Digital Transformation of Oncology Clinical Research. Journal of Clinical Research, v. 5, p. 1-2, 2021.
Suilane Coelho Ribeiro Oliveira, Camila Motta Venchiarutti Moniz, Rachel Riechelmann, Alexandra Kichfy Alex, Maria Ignez Braghirolli, Giovanni Bariani, Caio Nahas, Paulo Marcelo Gehm Hoff. Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal. Journal of Gastrointestinal Cancer, volume 47, pages 75–81(2016).
Paulo M Hoff, Renata Coudry, Camila Motta Venchiarutti Moniz. Pathology of anal cancer. Surgical Oncology Clinics 26 (1), 57-71 (2017).
Abraão Dornellas; Renata C. Bonadio; Priscila M. G. Moraes; Maria I. Braghiroli; Rodrigo P. Polizio; Paulo M. Hoff; Camila M. V. Moniz. Feasibility and Safety of 3-Weekly Carboplatin/Paclitaxel Regimen in Advanced Squamous cell Carcinoma of the Anal Canal. Clinical Oncology and Research, v. 4, p. 1-5, 2021.
Moniz CMV, Riechelmann RP, Oliveira SCR, Bariani GM, Rivelli TG, Ortega C, Pereira AAL, Meireles SI, Franco R, Chen A, Bonadio RC, Nahas C, Sabbaga J, Coudry RA, Braghiroli MI, Hoff PM. A Prospective Cohort Study of Biomarkers in Squamous Cell Carcinoma of the Anal Canal (SCCAC) and their Influence on Treatment Outcomes. J Cancer. 2021 Oct 16;12(23):7018-7025. PMID: 34729104; PMCID: PMC8558650.
Teo MY, Mota JM, Whiting KA, Li HA, Funt SA, Lee CH, Solit DB, Al-Ahmadie K, Milowsky MI, Balar AV, Pietzak E, Dalbagni G, Bochner BH, Ostrovnaya I, Bajorin DF, Rosenberg JE, Iyer G. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. Eur Urol. 2020;78(6):907-915.
Mota JM, Leite CA, Souza LE, Melo PH, Nascimento DC, de-Deus-Wagatsuma V, Temporal J, Figueiredo F, Noushmehr H, Alves-Filho JC, Cunha FQ, Rego EM. Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice. Cancer Immunol Res. 2016;4(4):312-22.
Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida W, Linton E, Lee E, Barnes SD, Chen A, Mao N, Wongvipat J, Choi D, Chen X, Zhao H, Manova-Todorova K, Stanchina E, Taplin ME, Balk SP, Rathkopf DE, Gopalan A, Carver BS, Mu P, Jiang X, Watson PA, Sawyers CL. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. 2020;38(2):279-296.e9.
Mota JM, Barnett E, Nauseef J, Nguyen N, Stopsack KH, Wibmer A, Flynn JR, Heller F, Danila DC, Rathkopf D, Slovin S, Kantoff PW, Scher HI, Morris MJ, Schultz N, Solit DB, Abida W. Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. JCO Precis Oncol. 2020; 4:355-366. Epub 2020 Apr 16.
Morris MJ, Mota JM, Lacuna K, Hilden P, Gleave M, Carducci MA, Saad F, Cohn ED, Filipenko J, Heller G, Shore N, Armstrong AJ, Scher HI. Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). Eur Urol Oncol. 2021;4(4):543-552.
Evangelista, A.F.; Vannier-Santos, M.A.; de Assis Silva, G.S.; Silva, D. N.; Juiz, P. J. L.; Nonaka, C. K. V.; Santos, R.R; Soares, M.B.P Villarreal, C. F.Bone marrow-derived mesenchymal stem/stromal cells reverse the sensorial diabetic neuropathy via modulation of spinal neuroinflammatory cascades. J Neuroinflammation 15, 189 (2018).
Nonaka, C.K.V.; Sampaio, G.L.; de Aragão França, L.; Cavalcante, B.R.; Silva, K.N.; Khouri, R.; Torres, F.G.; Meira, C.S.; de Souza Santos, E.; Macedo, C.T.; Paredes, B.D.; Rocha, V.P.C.; Rogatto, S.R.; Ribeiro dos Santos, R.; Souza, B.S.d.F.; Soares, M.B.P. Therapeutic miR-21 Silencing Reduces Cardiac Fibrosis and Modulates Inflammatory Response in Chronic Chagas Disease. Int. J. Mol. Sci. 2021, 22, 3307.
Nonaka, C.K.V.; Macêdo, C.T.; Cavalcante, B.R.R.; Alcântara, A.C.d.; Silva, D.N.; Bezerra, M.d.R.; Caria, A.C.I.; Tavora, F.R.F.; Neto, J.D.d.S.; Noya-Rabelo, M.M.; Rogatto, S.R.; Ribeiro dos Santos, R.; Souza, B.S.d.F.; Soares, M.B.P. Circulating miRNAs as Potential Biomarkers Associated with Cardiac Remodeling and Fibrosis in Chagas Disease Cardiomyopathy. Int. J. Mol. Sci. 2019, 20, 4064.
Improta Caria, A.C.; Nonaka, C.K.V.; Pereira, C.S.; Soares, M.B.P.; Macambira, S.G.; Souza, B.S.d.F. Exercise Training-Induced Changes in MicroRNAs: Beneficial Regulatory Effects in Hypertension, Type 2 Diabetes, and Obesity. Int. J. Mol. Sci. 2018, 19, 3608.
Nonaka CKV, Franco MM, Gräf T, de Lorenzo Barcia CA, de Ávila Mendonça RN, de Sousa KAF, Neiva LMC, Fosenca V, Mendes AVA, de Aguiar RS, Giovanetti M, de Freitas Souza BS. Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil. Emerg Infect Dis. 2021 May;27(5):1522-1524. Epub 2021 Feb 19. PMID: 33605869; PMCID: PMC8084516.
Silveira de Souza A., de Oliveira-Souza R., Moll J., Tovar-Moll F., Andreiuolo P.A., Bottino C.M.C.. Contribution of 1H Spectroscopy to a Brief Cognitive-Functional Test Battery for the Diagnosis of Mild Alzheimer’s Disease. Dement Geriatr Cogn Disord 2011;32:351–361.
Souza AS, Oliveira-Szjenfeld PS, Melo ASO, Souza LAM, Batista AGM, Tovar-Moll F. Imaging findings in congenital Zika virus infection syndrome: an update. Child’s Nervous System 2018; 34:85-93.
Drummond C, Coutinho G, Monteiro MC, Assuncao N, Teldeschi A, de Souza AS, Oliveira N, Bramati I, Sudo FK, Vanderboght B, Brandao CO, Fonseca RP, de Oliveira-Souza R, et al. Narrative impairment, white matter damage and CSF biomarkers in the Alzheimer’s disease spectrum. Aging (Albany NY). 2019;11:9188-9208.
Sudo FK, de Souza AS, Drummond C, Assuncao N, Teldeschi A, Oliveira N, et al. Inter-method and anatomical correlates of episodic memory tests in the Alzheimer’s Disease spectrum. PLoS ONE 2019; 14(10): e0223731.
Calil V, Souza AS, Sudo FK, Santiago-Bravo G, Assunção N, Drummond C, et al. Anosognosia for memory in dementia with Lewy bodies compared with Alzheimer’s disease. International Journal of Geriatric Psychiatry 2021; 36(7):1059-1064.
Silveira DRA, Quek L, Santos IS, Corby A, Coelho-Silva JL, Pereira-Martins DA, Vallance G, Brown B, Nardinelli L, Silva WF, Velloso EDRP, Lucena-Araujo AR, Traina F, Peniket A, Vyas P, Rego EM, Bendit I, Rocha V. Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. Blood Adv. 2020 May 26;4(10):2339-2350. PMID: 32453839
Balassa K, Rocha V. Anticancer cellular immunotherapies derived from umbilical cord blood. Expert Opin Biol Ther. 2018 Feb;18(2):121-134. Epub 2017 Nov 9. PMID: 29103317 Review.
Buss LF, Prete CA Jr, Abrahim CMM, Mendrone A Jr, Salomon T, de Almeida-Neto C, França RFO, Belotti MC, Carvalho MPSS, Costa AG, Crispim MAE, Ferreira SC, Fraiji NA, Gurzenda S, Whittaker C, Kamaura LT, Takecian PL, da Silva Peixoto P, Oikawa MK, Nishiya AS, Rocha V, Salles NA, de Souza Santos AA, da Silva MA, Custer B, Parag KV, Barral-Netto M, Kraemer MUG, Pereira RHM, Pybus OG, Busch MP, Castro MC, Dye C, Nascimento VH, Faria NR, Sabino EC. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science. 2021 Jan 15;371(6526):288-292. Epub 2020 Dec 8. PMID: 33293339; PMCID: PMC7857406.
Fatobene G, Rocha V, St Martin A, Hamadani M, Robinson S, Bashey A, Boumendil A, Brunstein C, Castagna L, Dominietto A, Finel H, Chalandon Y, Kenzey C, Kharfan-Dabaja M, Labussière-Wallet H, Moraleda JM, Pastano R, Perales MA, El Ayoubi HR, Ruggeri A, Sureda A, Volt F, Yakoub-Agha I, Zhang MJ, Gluckman E, Montoto S, Eapen M. Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. J Clin Oncol. 2020 May 10;38(14):1518-1526. Epub 2020 Feb 7. Erratum in: J Clin Oncol. 2020 Dec 1;38(34):4130. Erratum in: J Clin Oncol. 2021 Jan 20;39(3):258. PMID: 32031876; PMCID: PMC7213591.
Fatobene G, Volt F, Moreira F, Mariano L, Chevallier P, Furst S, Labussière-Wallet H, de la Tour RP, Deconinck E, Cluzeau T, Russell N, Karakasis D, Forcade E, Ruggeri A, Gluckman E, Rocha V. Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases. Blood Adv. 2020 Dec 22;4(24):6327-6335. PMID: 33351128; PMCID: PMC7756987.
Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, Fagerberg J, Bruno R. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol. 2009 Sep 1;27(25):4103-8. Epub 2009 Jul 27. PMID: 19636014.
Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4147-53. PMID: 16857785.
Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006 May 1;24(13):2065-72. PMID: 16648507
Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001 Apr 15;19(8):2282-92.
H.J. Schmoll, E. Van Cutsem, A. Stein, V. Valentini, B. Glimelius, K. Haustermans, B. Nordlinger, C.J. van de Velde, J. Balmana, J. Regula, I.D. Nagtegaal, R.G. Beets-Tan, D. Arnold, F. Ciardiello, P. Hoff, D. Kerr, C.H. Köhne, R. Labianca, T. Price, W. Scheithauer, A. Sobrero, J. Tabernero, D. Aderka, S. Barroso, G. Bodoky, J.Y. Douillard, H. El Ghazaly, J. Gallardo, A. Garin, R. Glynne-Jones, K. Jordan, A. Meshcheryakov, D. Papamichail, P. Pfeiffer, I. Souglakos, S. Turhal, A. Cervantes. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making, Annals of Oncology, Volume 23, Issue 10, 2012, Pages 2479-2516, ISSN 0923-7534.
Thomé CH, Ferreira GA, Pereira-Martins DA, Dos Santos GA, Ortiz CA, de Souza LEB, Sobral LM, Silva CLA, Scheucher PS, Gil CD, Leopoldino AM, Silveira DRA, Coelho-Silva JL, Traina F, Koury LC, Melo RAM, Bittencourt R, Pagnano K, Pasquini R, Nunes EC, Fagundes EM, Gloria ABF, Kerbauy FR, Chauffaille ML, Keating A, Tallman MS, Ribeiro RC, Dillon R, Ganser A, Löwenberg B, Valk P, Lo-Coco F, Sanz MA, Berliner N, Faça VM, Rego EM. NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. Sci Rep. 2020 Jun 25;10(1):10315. PMID: 32587277; PMCID: PMC7316767.
Weinhäuser I, Pereira-Martins DA, Ortiz C, Silveira DR, Simões LAA, Bianco TM, Araujo CL, Koury LC, Melo RAM, Bittencourt RI, Pagnano K, Pasquini R, Nunes EC, Fagundes EM, Gloria AB, Kerbauy F, Chauffaille ML, Keating A, Tallman MS, Ribeiro RC, Dillon R, Ganser A, Löwenberg B, Valk P, Lo-Coco F, Sanz MA, Berliner N, Ammatuna E, Lucena-Araujo AR, Schuringa JJ, Rego EM. Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia. Cancers (Basel). 2020 Oct 27;12(11):3134.
Barna, M., Pusic, A., Zollo, O. , Costa, M., Kondrashov, N., Rego, E., Rao, P.H., Ruggero, D.. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 2008; 456, 971–975.
Rego EM, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte Mdel R, Jacomo RH, Gutiérrez- Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille Mde L, Chiattone CS, Martinez L, Meillón LA, Gómez-Almaguer D, Kwaan HC, Garcés-Eisele J, Gallagher R, Niemeyer CM, Schrier SL, Tallman M, Grimwade D, Ganser A, Berliner N,, Ribeiro RC, Lo-Coco F, Löwenberg B, Sanz MA. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood. 2013;121(11):1935-43
Rego EM, Wang ZG, Peruzzi D, He LZ, Cordon-Cardo C, Pandolfi PP. Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med. 2001;193(4):521-29.
